Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
Clinical trial NCT02509507 · COMPLETED
Trial details
- NCT number
- NCT02509507
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-05
- Primary completion
- 2022-02-14
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.